Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pahr Therapeutics
Boston, Massachusetts, United Statespahrtx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Pahr Therapeutics is developing novel small molecule therapeutics for pulmonary arterial hypertension (PAH) and plans to enter clinical studies early next year. The company leverages research from the National Cerebral and Cardiovascular Center in Osaka, Japan, and was launched with significant venture capital backing[2].
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
RA Capital Management (incubation/operational partnership[2])National Cerebral and Cardiovascular Center (founder academic institution[2])
Beyond the preview
Go deeper on Pahr Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pahr Therapeutics.